SCHEMBL162373

SCHEMBL162373

CNC(=O)c1nccc([O])n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 3/20 0.39
PTPN11 Q06124 1/20 0.36
KDR P35968 1/20 0.36
HPGD P15428 2/20 0.36
PSMD14 O00487 1/20 0.36
STAMBP O95630 1/20 0.36
COPS5 Q92905 1/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
P2RX7 Q99572 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
CNR1 P21554 1/20 0.35
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
RIPK1 Q13546 1/20 0.34
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210828 0.81 ALOX15 (0.41) PLK1PTPN11KDRKDM4EGAA
SCHEMBL162918 0.80 CNR1 (0.39) HPGDKDM4EGAAP2RX7HDAC6
SCHEMBL163732 0.80 FDPS (0.41) KDM4ECNR1RIPK1TSHRSMN1; SMN2
SCHEMBL161652 0.80 SMN1; SMN2 (0.39) HPGDKDM4EGAARIPK1SMN1; SMN2
SCHEMBL282078 0.79 L3MBTL1 (0.38) PLK1PTPN11KDRHPGDKDM4E
SCHEMBL162211 0.78 HIF1A (0.42) HPGDKDM4EGAARIPK1HTT
SCHEMBL165741 0.77 KDM4E (0.41) PSMD14KDM4EGAATSHRHTT
SCHEMBL23772028 0.77 LMNA (0.40) PLK1PTPN11KDRHPGDKDM4E
SCHEMBL6635914 0.77 KDR (0.44) PLK1KDRKDM4ESMN1; SMN2
SCHEMBL25692403 0.77 KDR (0.37) PLK1PTPN11KDRHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 PLK1 1381/4885PTPN11 3886/4885KDR 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.